echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Express US$700 million to help AI-driven drug development for "gradual freezing", Eli Lilly and Verge reached a partnership

    Express US$700 million to help AI-driven drug development for "gradual freezing", Eli Lilly and Verge reached a partnership

    • Last Update: 2021-08-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Today, Verge Genomics, which is committed to using artificial intelligence to drive drug discovery and development and focusing on serious genetic diseases, announced that it has reached a three-year cooperation with Eli Lilly and Company to research and develop treatments for amyotrophic lateral cords.
    A new type of treatment for sclerosis (ALS)
    .

    According to the terms of the agreement, Verge will receive an upfront payment of US$25 million, equity investment and potential near-term payments, an additional milestone value of US$694 million, and possible royalties
    .



    ALS is also known as "gradual freezing syndrome".
    The average life expectancy of patients is about 2 to 5 years.
    There is currently no cure for this disease


    .


    In this collaboration, Verge will use its "all-in-human" platform to discover and verify new targets for ALS
    .
    This platform is based on a data set of transcriptomes in the brains of patients with a variety of neurodegenerative diseases


    .



    "Through cooperation with Eli Lilly, we will test the potential of using human data and machine learning to overcome the transformational barriers of challenging and complex biological diseases
    .
    " said Alice Zhang, CEO and co-founder of Verge Genomics


    .



    Related reading: Interview with Zhang Xinli, the 35 largest technology innovators of the year: Seeing opportunities, don't be afraid to chase

    "Verge Genomics is advancing an innovative method to identify high-potential drug targets
    .
    They are validated through artificial intelligence algorithms and large human databases


    .


    Reference materials:

    Reference materials:

    [1] Verge Genomics Announces Three-Year Collaboration With Lilly to Discover and Develop Novel Treatments Using Its AI-Driven All-in-Human Platform.
    Retrieved July 8, 2021, from https:// /20210708005085/en/Verge-Genomics-Announces-Three-Year-Collaboration-With-Lilly-to-Discover-and-Develop-Novel-Treatments-Using-Its-AI-Driven-All-in-Human-Platform

    [1] Verge Genomics Announces Three-Year Collaboration With Lilly to Discover and Develop Novel Treatments Using Its AI-Driven All-in-Human Platform.


    Retrieved July 8, 2021, from https:// /20210708005085/en/Verge-Genomics-Announces-Three-Year-Collaboration-With-Lilly-to-Discover-and-Develop-Novel-Treatments-Using-Its-AI-Driven-All-in-Human-Platform
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.